The WSJ article, using data from DealForma, discusses how major pharmaceutical companies have scaled down their acquisition strategies in 2024, focusing on smaller targets priced at $5 billion or less, primarily due to tighter regulatory scrutiny and a smaller pool of large-scale acquisition targets. Check out WSJ’s article.
